BiogenBIIBEarnings & Financial Report
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for ...
Revenue
$2.5B
Gross Profit
$1.9B
Operating Profit
$291.5M
Net Profit
$266.7M
Gross Margin
76.2%
Operating Margin
11.9%
Net Margin
10.9%
YoY Growth
2.9%
EPS
$1.82
Biogen Q4 FY2024 Financial Summary
Biogen reported revenue of $2.5B (up 2.9% YoY) for Q4 FY2024, with a net profit of $266.7M (up 6.8% YoY) (10.9% margin). Cost of goods sold was $583.5M, operating expenses totaled $1.6B.
Key Financial Metrics
| Total Revenue | $2.5B |
|---|---|
| Net Profit | $266.7M |
| Gross Margin | 76.2% |
| Operating Margin | 11.9% |
| Report Period | Q4 FY2024 |
Revenue Breakdown
Biogen Q4 FY2024 revenue of $2.5B breaks down across 11 segments, led by Products at $1.8B (74.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $1.8B | 74.7% |
| SPINRAZA | $166.8M | 6.8% |
| BENEPALI | $125.0M | 5.1% |
| AVONEX | $107.3M | 4.4% |
| SKYCLARYS | $70.7M | 2.9% |
| IMRALDI | $51.0M | 2.1% |
| TECFIDERA | $41.3M | 1.7% |
| PLEGRIDY | $26.7M | 1.1% |
| FLIXABI | $16.1M | 0.7% |
| FAMPYRA | $14.4M | 0.6% |
| QALSODY | $6.4M | 0.3% |
Biogen Revenue by Segment — Quarterly Trend
Biogen revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and SPINRAZA) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Products | — | $1.7B | $1.8B | $1.9B |
| SPINRAZA | — | — | $153.2M | $149.3M |
| BENEPALI | — | — | $121.9M | $112.1M |
| AVONEX | — | $119.2M | $133.4M | $121.7M |
| SKYCLARYS | — | $88.9M | $74.6M | $78.0M |
Biogen Annual Revenue by Year
Biogen annual revenue history includes year-by-year totals (for example, 2025 revenue was $9.9B).
| Year | Annual Revenue |
|---|---|
| 2025 | $9.9B |
| 2024 | $9.7B |
| 2023 | $9.8B |
| 2022 | $10.2B |
Biogen Quarterly Revenue & Net Profit History
Biogen results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $2.5B | +2.0% | $319.5M | 12.9% |
| Q4 FY2025 | $2.3B | -7.1% | $-48.9M | -2.1% |
| Q3 FY2025 | $2.5B | +2.8% | $466.5M | 18.4% |
| Q2 FY2025 | $2.6B | +7.3% | $634.8M | 24.0% |
| Q1 FY2025 | $2.4B | +6.1% | $240.5M | 9.9% |
| Q4 FY2024 | $2.5B | +2.9% | $266.7M | 10.9% |
| Q3 FY2024 | $2.5B | -2.5% | $388.5M | 15.8% |
| Q2 FY2024 | $2.5B | +0.4% | $583.6M | 23.7% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.46B | $2.47B | $2.45B | $2.43B | $2.65B | $2.53B | $2.28B | $2.48B |
| YoY Growth | 0.4% | -2.5% | 2.9% | 6.1% | 7.3% | 2.8% | -7.1% | 2.0% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $26.80B | $28.31B | $28.05B | $28.03B | $28.33B | $29.21B | $29.44B | $29.48B |
| Liabilities | $10.91B | $11.95B | $11.33B | $11.05B | $10.70B | $11.00B | $11.18B | $10.83B |
| Equity | $15.89B | $16.36B | $16.72B | $16.98B | $17.63B | $18.21B | $18.26B | $18.65B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $625.8M | $935.6M | $760.9M | $259.3M | $160.9M | $1.27B | $511.9M |